Advisornet Financial’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.28M | Buy |
2,864
+596
| +26% | +$278K | 0.07% | 224 |
|
|
2025
Q4 | $1.03M | Buy |
2,268
+69
| +3% | +$29.7K | 0.05% | 256 |
|
|
2025
Q3 | $861K | Buy |
2,199
+525
| +31% | +$219K | 0.05% | 276 |
|
|
2025
Q2 | $745K | Buy |
1,674
+201
| +14% | +$92.6K | 0.05% | 291 |
|
|
2025
Q1 | $714K | Buy |
1,473
+117
| +9% | +$54.5K | 0.05% | 275 |
|
|
2024
Q4 | $546K | Buy |
1,356
+16
| +1% | +$7.42K | 0.05% | 298 |
|
|
2024
Q3 | $623K | Buy |
1,340
+72
| +6% | +$34.6K | 0.05% | 289 |
|
|
2024
Q2 | $594K | Buy |
1,268
+82
| +7% | +$35.6K | 0.05% | 274 |
|
|
2024
Q1 | $496K | Buy |
1,186
+53
| +5% | +$22.4K | 0.05% | 309 |
|
|
2023
Q4 | $461K | Buy |
1,133
+9
| +0.8% | +$3.33K | 0.04% | 332 |
|
|
2023
Q3 | $391K | Sell |
1,124
-34
| -3% | -$11.9K | 0.04% | 339 |
|
|
2023
Q2 | $408K | Sell |
1,158
-31
| -3% | -$10.4K | 0.03% | 339 |
|
|
2023
Q1 | $375K | Sell |
1,189
-12
| -1% | -$3.6K | 0.03% | 345 |
|
|
2022
Q4 | $347K | Buy |
1,201
+48
| +4% | +$14.6K | 0.03% | 358 |
|
|
2022
Q3 | $334K | Buy |
1,153
+58
| +5% | +$16.7K | 0.03% | 397 |
|
|
2022
Q2 | $309K | Buy |
1,095
+22
| +2% | +$5.89K | 0.03% | 411 |
|
|
2022
Q1 | $280K | Buy |
1,073
+7
| +0.7% | +$1.66K | 0.02% | 477 |
|
|
2021
Q4 | $234K | Buy |
1,066
+113
| +12% | +$22K | 0.01% | 568 |
|
|
2021
Q3 | $173K | Sell |
953
-495
| -34% | -$96.6K | 0.01% | 624 |
|
|
2021
Q2 | $292K | Buy |
1,448
+78
| +6% | +$16.3K | 0.02% | 488 |
|
|
2021
Q1 | $294K | Buy |
1,370
+8
| +0.6% | +$1.76K | 0.02% | 458 |
|
|
2020
Q4 | $322K | Sell |
1,362
-4
| -0.3% | -$918 | 0.03% | 415 |
|
|
2020
Q3 | $372K | Sell |
1,366
-187
| -12% | -$51.6K | 0.03% | 382 |
|
|
2020
Q2 | $451K | Sell |
1,553
-77
| -5% | -$20.9K | 0.04% | 358 |
|
|
2020
Q1 | $388K | Buy |
1,630
+68
| +4% | +$15.6K | 0.04% | 359 |
|
|
2019
Q4 | $342K | Sell |
1,562
-148
| -9% | -$30K | 0.03% | 399 |
|
|
2019
Q3 | $290K | Buy |
1,710
+325
| +23% | +$57.5K | 0.03% | 430 |
|
|
2019
Q2 | $254K | Hold |
1,385
| – | – | 0.03% | 410 |
|
|
2019
Q1 | $255K | Buy |
1,385
+27
| +2% | +$4.99K | 0.03% | 389 |
|
|
2018
Q4 | $225K | Sell |
1,358
-32
| -2% | -$5.54K | 0.03% | 386 |
|
|
2018
Q3 | $268K | Sell |
1,390
-164
| -11% | -$29.2K | 0.03% | 367 |
|
|
2018
Q2 | $264K | Buy |
1,554
+205
| +15% | +$31.8K | 0.04% | 338 |
|
|
2018
Q1 | $220K | Hold |
1,349
| – | – | 0.03% | 376 |
|
|
2017
Q4 | $202K | Buy |
+1,349
| New | +$200K | 0.03% | 350 |
|
Other funds holding VRTX
VCM
VPM
Advisornet Financial's VRTX Position: Q1 2026 in Review
Advisornet Financial increased its Vertex Pharmaceuticals (VRTX) stake by 26% in Q1 2026, buying an estimated $278K and bringing the position to 2,864 shares worth $1.28M. The position accounts for 0.07% of the portfolio, ranked #224.
Advisornet Financial first reported a position in VRTX in Q4 2017 and has held it in 34 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Advisornet Financial held 2,864 shares of Vertex Pharmaceuticals worth $1.28M as of Q1 2026.
- Advisornet Financial bought 596 Vertex Pharmaceuticals shares in Q1 2026, an estimated $278K.
- Vertex Pharmaceuticals made up 0.07% of Advisornet Financial's portfolio in Q1 2026, its #224 holding.
- Advisornet Financial first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Advisornet Financial's 13F filing for Q1 2026, filed 17 Apr 2026.